Wednesday, June 22, 2016

Medicare Part D spending on compounded drugs is skyrocketing - STAT STAT‎ - 4 hours ago

1 comment:

Anonymous said...

Good to see the rise in spending is not being misread as an increase in demand for non-FDA-approved drugs, i.e., products that risk reaching patients without structured vetting for safety or effectiveness and frequently accompanied by layers of disclaimed warranty unknown to would-be and actual patients and prescribers. The skyrocketing spending appears to be the result of repurposed, questionable business models that exploit public payers (tax payers) reminiscent of the standardized, pre-printed prescriptions for compounded Part B nebulizer drugs from the days of yore.